160 HEALTH (02656.HK): Completes delivery of RMB 12.2 million integrated healthcare and AI computing solution, moves into medical AI agent business

NewTimeSpace News: On 14 September 2026, 160 Health International Limited (stock code: 02656) issued a voluntary announcement stating that the Group had recently, through its domestic subsidiary, completed the delivery of an integrated solution in a total amount of RMB 12.2 million to a customer, a big health enterprise focusing on the research and development of smart wearable health devices, and had obtained an acceptance certificate issued by the customer. The announcement stated that, to the best of the directors' knowledge, information and belief, the customer and its ultimate beneficial owner are third parties independent of the Company and its connected persons.

Under the order, the Group provided the customer with an integrated solution comprising a smart health monitoring system, computing power infrastructure and integrated commissioning services. Following completion of delivery, the solution will support real-time access, cleansing and storage of high-frequency vital sign data from the customer's massive terminal devices, and will rely on computing power to deliver core functions including AI health inference, risk alerts and user health profile management. The Group described the delivery as an integrated solution of "medical AI agent + hardware + integrated commissioning services", providing healthcare customers with integrated delivery of AI medical products together with computing power infrastructure.

The Group has long been engaged in the internet healthcare sector and states that it has accumulated substantial invention patents, software copyrights and other intellectual property. It has developed the 160 AI Hospital through deep integration and upgrading of AI applications and launched the "160 AI Hospital" operational cooperation business model, forming an integrated "platform + AI agent + operations" model that brings AI agents into internal operational processes including product research and development, content production and customer services. Building on this, the Group has combined its own smart health monitoring system with computing power infrastructure to further enrich its product matrix.

The Board considers the successful delivery and acceptance of the solution to be an important exploration and key breakthrough for the Group in the new business path of integrating healthcare with AI computing power, and notes that in scenarios such as smart wearable health monitoring and chronic disease management, the coordinated deployment of AI software platforms and computing power infrastructure has become a key step for healthcare enterprise customers to achieve a closed business loop. The Company cautioned shareholders and potential investors that its business development in this field remains at an early stage, that the delivery and acceptance of the order represent the completion of a single business order and have not yet formed a scaled or recurring revenue model, that the specific amount and impact on its overall financial position cannot yet be accurately estimated, and that there is no assurance of sustainable revenue or profit contribution in the future. The order and the transactions thereunder do not constitute a discloseable transaction under Chapter 14 of the Listing Rules nor a connected transaction under Chapter 14A.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.